Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma

NCT07162012 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

NK/T-cell Lymphoma
Peripheral T-cell Lymphoma (PTCL)
DLBCL

Interventions

DRUG: EBV TCR-T

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine